Marker Therapeutics is trading 6.5% down at $1.15 despite no fresh company-specific headlines or fundamental updates.
- The decline appears to be a standalone move in the thinly traded micro-cap name, underperforming a broadly rising biotech sector and strong overall U.S. market.
- There are no earnings, FDA updates, or analyst actions reported for August 5, 2026, that explain the downward price action.